Interesting blend of simulations, preclinical, and clinical data in order to make smart go/no go development decisions.
Best Practices
The results showed that the new drug was unlikely to outperform its main competitor; Pfizer discontinued development. The modeling project supported a more confident decision without investment in additional trials and allowed team members to re-deploy to other programs. It provided an enduring, evolving knowledge repository to support future development projects. DMX enabled team members to evaluate complex product tradeoffs and ask targeted what-if questions in real time.
Comments